December 13, 2010
MESSAGE FROM THE DIRECTOR
Philip H. Howe, PhD Appointed Case CCC Associate Director for Basic Research at the LRI
The Case CCC announces the appointment of Philip H. Howe, PhD, Staff in the Cancer Biology Department of the Lerner Research Institute, to the position of Case CCC Associate Director for Basic Research at the LRI. Janet Houghton, PhD, Chair of the Department of Cancer Biology, remains an active member of our scientific programs and provides her leadership and Cancer Center advocacy as department chair.
Phil is an active investigator in cancer signaling including TGF–beta, Wnt, FoxO3 and related pathways. He is organizing a TGF–beta multi investigator effort.
Please contact Phil for strategic advice if you plan to form a multi–investigator working group. The Cancer Center will support these activities, with assistance for meetings, collaborations and grant applications. Likewise, with these initiatives, Phil will recommend areas for investment to the Cancer Center Senior Leaders and will assist in developing RFAs for focused research ideas.
Please join me in congratulating Phil and, when he calls on you, offer your enthusiastic support and creative ideas for cutting edge cancer research. He and I are available to meet with members any time.
Thank you for your commitment to cancer research at the Case Comprehensive Cancer Center.
Stan Gerson, MD
Click here to read the full announcement.
CASE CCC IN THE NEWS
Cancer Doctors Urge Caution Over Taking Daily Aspirin
CWRU News Center
Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health (NIH), in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.
Researchers Mark Chance, PhD, professor of physiology and biophysics, director of the Center for Proteomics and Bioinformatics, and interim chair of the Department of Genetics, and W. Henry Boom, MD, professor of medicine and director of the Tuberculosis Research Unit, are working to tackle the easily transmissible, and often deadly, Mycobacterium tuberculosis (MTB)...
The Case Comprehensive Cancer Center was awarded a new $2.5 million grant from the National Cancer Institute (NCI) to evaluate the introduction and expression of the modified MGMT gene in hematopoietic stem cells in an effort to improve efficacy of chemotherapy for glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain tumor in humans...
This trial will build on the more than two decades of research by Stanton Gerson, MD, principal investigator of the study, the Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, and director of the NCI-designated Case Comprehensive Cancer Center. ..
In another example of a team science approach, members of the Case Comprehensive Cancer Center have been tapped to join an important NCI multisite prospective study of all grade II, III and IV glioma patients within the state... researchers will be part of The Cancer Genome Atlas (TCGA) Project, which is a national comprehensive and coordinated effort to accelerate understanding of the genetics of cancer using innovative genome analysis technologies... Under the direction of principal investigator Jill Barnholtz-Sloan, PhD, assistant professor of general medical sciences, newly diagnosed patients with gliomas will be prospectively accrued from her Ohio Brain Tumor Study (OBTS), a multisite study within Ohio...
Case Western Reserve faculty have worked closely with TCGA for many years; Barnholtz-Sloan and Andrew Sloan, MD, the Peter D. Cristal Chair in Neurosurgery at the School of Medicine and director of the Brain Tumor and Neuro-Oncology Center at UHCMC are active members of the TCGA Glioma Disease Expert Working groups... In addition, Neal Meropol, MD, Chief, Division of Hematology and Oncology, Case Western Reserve University School of Medicine and UH Case Medical Center and Associate Director for Clinical Research, Case Comprehensive Cancer Center, is a member of the TCGA Colorectal Cancer Disease Expert Working group.
The Department of Bioethics was awarded a $2.5 million continuation grant from the National Human Genome Research Institute that will extend funding for its Center for Genetic Research Ethics and Law (CGREAL) for an additional four years... It is co-directed through the collaborative partnership of Patricia Marshall, PhD, professor of bioethics, and Richard Sharp, PhD, director of research in the Department of Bioethics at the Cleveland Clinic. The mission of the CGREAL is to conduct transdisciplinary studies of ethical and societal issues in human genetic research and the introduction of new genetic technologies into patient care and public health; additionally it seeks to prepare young scholars for successful careers in Ethical, Legal, Social Issues (ELSI) research...
Basic, Clinical, or Translational Human Tissue Based Cancer Research Project Awards
The Case Comprehensive Cancer Center is pleased to announce the recipients of pilot funding to support basic, clinical or translational human tissue based research. The purpose of these awards is to foster collaborations and to promote and increase institution-wide capacity and competitiveness in research.
James Jacobberger, PhD: Cell Signaling as an Acute Myeloid Leukemia Biomarker
Ruth Keri, PhD: Follistatin as an Inhibitor of Metastatic Progression in Breast Cancer
Andrew Sloan, MD: Targeted Proteomics to Predict Differential Glioblastoma Survival
Jill Barnholtz-Sloan, PhD: Development of Human Brain Tumor Tissue Microarrays
Ge Jin, PhD: Human β–defensins as Novel Biomarkers for Precancerous Lesions of Colorectal Cancer
Cheryl Thompson, PhD: A Biorepository for Research in Lung Cancer Risk, Detection and Prognosis
William Schiemann, PhD Oncogenic TGF–β Effectors are Novel Biomarkers for Recurrent Cancer
**All events are open to anyone interested in attending
Cancer Biology Invited Speaker Seminar
Hematology and Oncology Division Research Conference
Immunology Invited Speaker Seminar Series
Developmental Therapeutics Program Meeting
Taussig Cancer Institute Grand Rounds
Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ADDITIONAL UPCOMING SEMINARS & EVENTS
Active Living Research Annual Conference
Multilevel Interventions in Health Care: Building the Foundation for Future Research Goals
4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science
Call for Abstracts: 2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
Cancer Health Disparities Summit 2011
NCI Website on Transforming the NCI Clinical Trials Enterprise
The Institute of Medicine (IOM) issued a report in April 2010 about reinvigorating the NCI Cooperative Group Program. The NCI met with the Chairs for the US Cooperative Groups that conduct clinical trials on November 29 in Bethesda, MD, to begin to discuss the issues raised by the IOM as well as other stakeholders in the NCI Clinical Trials Enterprise.
The NCI has now launched a website to address general issues about transforming the Clinical Trials Enterprise and to begin the process of collecting data/input on these issues more specifically with various stakeholders over the next six months. The website can be accessed at: http://transformingtrials.cancer.gov/. The link to the information on transforming the program is listed under NCI's Clinical Trials Cooperative Group Program: Infrastructure in Transition. NCI will be making updates to the website as we move forward with this process. In the interim, if you have any questions or concerns, please contact: Meg Mooney, MD, Chief, NCI Clinical Investigations Branch at email@example.com.
ACS Joseph S. Silber Student Research Fellowship
The American Cancer Society East Central Division, Ohio, offers the Joseph S. Silber Student Research Fellowship to undergraduate and graduate science majors and first-year medical students to encourage their participation in a sponsor's team-oriented project in cancer research at a Cleveland-area institution. The purpose is to expose students early in their careers to the problem of cancer in hopes that cancer research will become a lifelong interest and and pursuit.
Deadline: January 28, 2011
MARK YOUR CALENDARS
Second Oncomine Workshop
The Second Oncomine workshop will occur on Tuesday December 14 from 2-3 pm in SOM E324. To derive any benefit from the workshop, you must be registered with www.oncomine.org. We will revisit the basics covered in the first workshop, and extend ourselves a little further. Don't miss this opportunity to learn how to make your next grant proposal look better. Places are limited contact Patrick.Leahy@case.edu to reserve your spot.
Cancer Imaging Nanotechnology Sub-group Meeting
Drs. Jim Basilion and Zhenghong Lee would like to extend an invitation to the Case Comprehensive Cancer Imaging Program members to attend the next meeting of the Cancer Imaging Nanotechnology Sub-Group. The meeting will take place January 10 from 4-5 pm in the CCIR Conference Room, Wearn B-37. Please contact Marianne Sperk with any questions.
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
AACR Basic Cancer Research Fellowships
SU2C Innovative Research Grants
NIH BULLETIN – Notices and Funding Opportunities
Reminder: Beginning January 1, 2011, the NIH Will Require Use of xTrain for the Electronic Submission of Appointment Forms and/or Termination Notices for Institutional Research Training and Career Awards, Individual Fellowships and Research Education Awards (NOT-OD-11-026)
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.